Solid Biosciences to Present at the Credit Suisse Healthcare Conference
CAMBRIDGE, Mass., Nov. 09, 2018 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will present at […]
Altura Energy Inc. Announces Third Quarter 2018 Results, Material Operating Cost Reduction and Record Corporate Production
CALGARY, Alberta, Nov. 09, 2018 (GLOBE NEWSWIRE) — Altura Energy Inc. (“Altura” or the “Corporation”) (TSXV: ATU) is pleased to […]
Enthusiast Gaming Closes Oversubscribed, Non-Brokered Private Placement of Convertible Debenture Units for $9 Million
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE […]
Oxford Immunotec Reports Third Quarter 2018 Financial Results
Closed transformative deal to sell U.S. laboratory services business to Quest Diagnostics T-SPOT®.TB tests sold in the third quarter exceeded […]
Kandi Technologies Reports Third Quarter 2018 Financial Results
– Q3 revenue increased 34.0% yoy to $38.0 million –– Q3 gross profit increased 29.2% yoy to $6.2 million – […]
PLUS™ Reveals its 2018 Holiday Limited Edition: Cranberry & Shortbread Gummies
Gift a Delicious, Consistent Cannabis Experience ADELANTO, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) — Plus Products Inc. (CSE: PLUS) (the […]
Antares Pharma Announces Data Presentation at the 2018 Sexual Medicine Society Scientific Annual Meeting
XYOSTED™ AMBULATORY BLOOD PRESURE ABSTRACT HAS BEEN SELECTED FOR POSTER PRESENTATION EWING, N.J., Nov. 09, 2018 (GLOBE NEWSWIRE) — Antares […]
Valeritas Reports Record Revenue for the Third Quarter 2018
– Company’s Third Consecutive Quarter with Greater than 30% Year-Over-Year Revenue Growth – BRIDGEWATER, N.J., Nov. 09, 2018 (GLOBE NEWSWIRE) […]
VBI Vaccines Announces Third Quarter 2018 Financial Results and Provides Corporate Update
— Completion of vaccination and enrollment in Sci-B-Vac® PROTECT and CONSTANT Phase 3 studies, respectively — — Encouraging early […]
CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology
–CRISPR Therapeutics Gains Additional Rights to MaxCyte’s Cell Engineering Technology to Develop CRISPR/Cas9-Based Cell Therapies in Immuno-Oncology– ZUG, Switzerland and […]
